The latest domestic price of Rucaparib

Rucaparib (Rucaparib) is used to treat ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (cancer of the lining of the abdominal organs). Rucaparib is sometimes used in these cases only if the patient's cancer has a specific genetic marker (an abnormal "BRCA" gene). Doctors testfor this gene in cancers. Rucaparib is also used to treat prostate cancer with BRCA gene abnormalities. Rucaparib is given for this condition when the cancer has spread to other parts of the body and surgery or other cancer treatments are not working or have stopped working.

In clinical studies, some people responded to rucaparib, but further research is needed. The pharmacokinetic profile of rucaparib monotherapy has been demonstrated in patients with advanced solid tumors, including advanced ovarian and prostate cancer. Due to the fragmentation-causing properties of PARP inhibitors, rucaparib has not been studied in healthy volunteers. In addition to PARP inhibition, rucapanib also demonstrated a PARP-independent cytotoxicity mechanism in cancer cells. Rucaparib has synergistic or additive effects both in vitro and in vivo when co-administered with other chemotherapeutic agents.

The original drug Rucapani has not yet been marketed in the country, so it has not entered the medical insurance coverage standards. The European version of rucapani original drug, specifications300mg*60 tablets sold overseas may cost more than 20,000 yuan per box (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheap generic rucapani drugs available overseas, and their pharmaceutical ingredients are basically the same as those of the original rucapani drug. For example, in India, the price of BDR pharmaceutical specifications of 300mg*60 tablets per box may be more than 6,000 yuan (the price may fluctuate due to exchange rate effects).